| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e5f6fcca8ffe1c128c5f179f3fa9e71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_440b3059c9bcd1d85fd383f9b2ae1b40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5af8fa682ec6ba593a62d8197a594694
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2008-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_114fa4e976dd51daa40eb391f05f44e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_298a5352f3f751748b8e83c1cd93cb84 |
| publicationDate |
2017-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9725514-B2 |
| titleOfInvention |
Chronic rejection inhibitor |
| abstract |
The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10874677-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10787507-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10800841-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10787511-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017022280-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10744201-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11667720-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10697883-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11136610-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11692037-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10913794-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11622969-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11021728-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11377678-B2 |
| priorityDate |
2007-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |